€0.34
Your prediction
Cellectar BioSciences Inc. Stock
Pros and Cons of Cellectar BioSciences Inc. in the next few years
Pros
Cons
Performance of Cellectar BioSciences Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cellectar BioSciences Inc. | -4.550% | 54.386% | 49.153% | -87.692% | 12.821% | -91.189% | - |
| Beximco Pharmaceuticals Ltd. GDR | 2.420% | -1.429% | 3.500% | -1.429% | 0.000% | -55.484% | -8.407% |
| SELLAS Life Sciences Group Inc | 0.140% | -5.305% | -6.176% | 9.846% | 51.753% | -47.673% | -52.918% |
| Eledon Pharmaceuticals Inc. | -5.150% | -1.449% | -4.225% | 8.800% | -33.333% | -8.108% | -67.433% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Analyzing the financials of Cellectar BioSciences, a player in the pharmaceutical sector, reveals a company that is currently operating in a challenging financial position. With a market capitalization of approximately $71.42 million, the figures present a mixed bag of opportunities and risks. A look into their income statement, balance sheet, and cash flow statement indicates a firm that is still in its developmental phase, struggling with profitability in a highly competitive field.
Market Capitalization: At about $71.42 million, Cellectar’s market cap places it in a relatively manageable territory for potential growth. Smaller market caps can lead to rapid appreciation in share value if positive news is forthcoming, especially in a volatile sector like pharmaceuticals.
Book Value: The book value per share of $0.274 indicates that, despite current operational challenges, the company's tangible assets may provide a cushion for investors. This value is critical in assessing the minimum the company is worth, which can be appealing for long-term investors.
Comments
